Pacific Edge Limited announced that it had substantially completed a commercial agreement with Te Whatu Ora - Southern for the use of its non-invasive Cxbladder genomic biomarker tests. At this stage the contract remains unsigned. The business case is currently with Te Whatu Ora -Southern Management Team and following that it will enter an approvals cycle.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.095 NZD | -6.86% | +5.56% | -18.80% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.80% | 47.03M | |
+44.48% | 55.07B | |
-0.86% | 41.79B | |
+43.79% | 40.22B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- PEB Stock
- News Pacific Edge Limited
- Pacific Edge Limited Completes a Commercial Agreement with Te Whatu Ora Southern